A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
第2相
早期終了
NCT06113328
| 対象疾患 | Non-segmental Vitiligo |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Merck Sharp & Dohme LLC |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 169 名 |
|---|
| 介入（薬剤） | MK-6194 |
|---|
| 開始日 | 2023年11月27日 |
|---|
| 完了日 | 2025年3月20日 |
|---|
| 結果公開日 | 2026年3月17日 |
|---|
概要
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24
Baseline and Week 24 · Percent change
| MK-6194 3 mg Q2W | -4.55 Percent change |
|---|
| MK-6194 3 mg Q4W | -12.13 Percent change |
|---|
| Placebo | -4.01 Percent change |
|---|
| p-value | 0.949 |
|---|
| Mean Difference (Final Values) | -0.55 (95% CI -17.47–16.38) |
|---|
Number of Participants Who Experienced an Adverse Event (AE)
Up to approximately 28 weeks · Participants
| MK-6194 3 mg Q2W | 51 Participants |
|---|
| MK-6194 3 mg Q4W | 47 Participants |
|---|
| Placebo | 44 Participants |
|---|
Number of Participants Who Discontinued Study Treatment Due to an AE
Up to approximately 24 weeks · Participants
| MK-6194 3 mg Q2W | 9 Participants |
|---|
| MK-6194 3 mg Q4W | 5 Participants |
|---|
| Placebo | 1 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。